IL6 and familial pancreatic carcinoma: To test our hypothesis that IL-6 is responsible for the activation of the STAT3 pathway in pancreatic cancer cells, we performed experiments where we neutralized the IL-6 receptors (IL-6Rs) using the IL-6R neutralizing monoclonal antibody Tocilizumab (Figure 5b).